Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies

Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease

(2018) Jose D. Pagan et al.   CELL

Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern

(2018) Nathalie Fournier et al.   mAbs

Antibodies to watch in 2018

(2018) Hélène Kaplon et al.   mAbs

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

(2018) Juan C. Almagro et al.   Frontiers in Immunology

Modulating IgG effector function by Fc glycan engineering

(2017) Tiezheng Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity

(2017) Taia T. Wang et al.   SCIENCE

A Functional Role for Antibodies in Tuberculosis

(2016) Lenette L. Lu et al.   CELL

Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities

(2016) Roy Jefferis   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines

(2016) Yusuke Mimura et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis

(2016) Yuhsuke Ohmi et al.   Nature Communications

At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody

(2016) Chuanfei Yu et al.   Scientific Reports

Characterization of monoclonal antibodies by a fast and easy liquid chromatography–mass spectrometry time-of-flight analysis on culture supernatant

(2015) Antoine Henninot et al.   ANALYTICAL BIOCHEMISTRY

Multi-Site N-glycan mapping study 1: Capillary electrophoresis – laser induced fluorescence

(2015) Ákos Szekrényes et al.   mAbs

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

(2015) Nathaniel Washburn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A common glycan structure on immunoglobulin G for enhancement of effector functions

(2015) Chin-Wei Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs

(2015) Benjamin M. Fiebiger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Structural Role of Antibody N-Glycosylation in Receptor Interactions

(2015) Ganesh P. Subedi et al.   STRUCTURE

A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors

(2015) Daniela Kao et al.   Cell Reports

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions

(2015) Céline Monnet et al.   Frontiers in Immunology

Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions

(2014) L. Baudino et al.   JOURNAL OF IMMUNOLOGY

Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins

(2014) Alysia A. Ahmed et al.   JOURNAL OF MOLECULAR BIOLOGY

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody

(2014) Céline Monnet et al.   mAbs

Type I and type II Fc receptors regulate innate and adaptive immunity

(2014) Andrew Pincetic et al.   NATURE IMMUNOLOGY

Restricted Motion of the Conserved Immunoglobulin G1 N-Glycan Is Essential for Efficient FcγRIIIa Binding

(2014) Ganesh P. Subedi et al.   STRUCTURE

Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies

(2014) Caitlin Gillis et al.   Frontiers in Immunology

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

(2013) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies

(2013) Xiaojie Yu et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities

(2013) Susan H. Tam et al.   mAbs

Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies

(2013) Gabriele Proetzel et al.   METHODS

Capillary electrophoresis in the N-glycosylation analysis of biopharmaceuticals

(2013) András Guttman   TRAC-TRENDS IN ANALYTICAL CHEMISTRY

The interactions of therapeutic antibodies with Fc receptors

(2012) Marcello Albanesi et al.   IMMUNOLOGY LETTERS

Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans

(2012) Marcella Yu et al.   mAbs

Fast analysis of recombinant monoclonal antibodies using IdeS proteolytic digestion and electrospray mass spectrometry

(2011) Guillaume Chevreux et al.   ANALYTICAL BIOCHEMISTRY

Molecular cloning, characterization, genomic organization and promoter analysis of the α1,6-fucosyltransferase gene (fut8) expressed in the rat hybridoma cell line YB2/0

(2011) Béatrice Teylaert et al.   BMC BIOTECHNOLOGY

High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans

(2011) A. M. Goetze et al.   GLYCOBIOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

(2011) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains

(2011) Jeroen J Lammerts van Bueren et al.   NATURE BIOTECHNOLOGY

Efficient mucosal vaccination mediated by the neonatal Fc receptor

(2011) Lilin Ye et al.   NATURE BIOTECHNOLOGY

NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic

(2011) Adam W Barb et al.   Nature Chemical Biology

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs

(2010) Robert M. Anthony et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Engineering host cell lines to reduce terminal sialylation of secreted antibodies

(2010) Michael F. Naso et al.   mAbs

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

(2009) Y. A. Yeung et al.   JOURNAL OF IMMUNOLOGY

Carbohydrate and Domain Architecture of an Immature Antibody Glycoform Exhibiting Enhanced Effector Functions

(2009) Max Crispin et al.   JOURNAL OF MOLECULAR BIOLOGY

Structural characterization of a human Fc fragment engineered for lack of effector functions

(2008) Vaheh Oganesyan et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

(2008) Christophe de Romeuf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

(2008) T Shantha Raju   CURRENT OPINION IN IMMUNOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY